NCT01843634已完成早期 1 期
A Pilot Study to Evaluate the Safety and Preliminary Evidence of a Therapeutic Effect of ODSH (2-0, 3-0, Desulfated Heparin) in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 发起方
- Chimerix
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Safety by incidence of serious events
研究概览
简要总结
This is an open-label pilot study evaluating the safety and preliminary evidence of a therapeutic effect of ODSH (2-0, 3-0 desulfated heparin) in conjunction with standard induction and consolidation therapy for acute myeloid leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed, previously untreated acute myeloid leukemia. Acute promyelocytic leukemia is excluded.
- •No prior chemotherapy for acute myeloid leukemia; however, prior hydroxyurea to control white blood cell count is allowed.
- •No prior chemotherapy or lenalinomide for treatment of myelodysplastic syndrome.
- •ECOG Performance status 0-2
- •Cardiac ejection fraction ≥ 50% (echocardiography or MUGA [multigated acquisition])
- •Adequate hepatic and renal function (AST [aminotransferase], ALT [alanine aminotransferase], bilirubin and creatinine < 2.5 x upper normal limit).
- •Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.
排除标准
- •Patients with acute promyelocytic leukemia
- •Patients with acute megakaryoblastic leukemia
- •Patients with CNS (central nervous system) leukemia
- •Presence of significant active infection or uncontrolled bleeding
- •Any coexisting major illness or organ failure which contraindicates the dose-intensive chemotherapy regimen prescribed by this protocol
- •Pre-existing liver disease that might impair ODSH clearance
- •History of other active malignant disease within 5 years, other than cured basal cell carcinoma of the skin, cured in situ carcinoma of the cervix, or localized prostate cancer that has received definitive therapy. Such prostate cancer patients who are receiving hormonal therapy are eligible
- •Use of recreational drugs or history of drug addiction, within the prior 6 months
- •Known history of positive hepatitis B surface antigens or hepatitis C antibodies
- •Known history of positive test for HIV (Human immunodeficiency virus) antibodies
- •Psychiatric or neurologic conditions that could impair ability to give proper informed consent
- •Presence of symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia
- •Presence of uncontrolled thrombotic or hemorrhagic disorder
- •A medical condition that requires the need to be on chronic anticoagulation
- •Presence of any other serious uncontrolled medical disorder
- •Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry
- •Pregnant or breast-feeding patients
- •Patient with childbearing potential not using adequate contraception
- •Hemorrhage risk that requires maintenance of platelet counts at 50,000/uL or higher.
- •Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
研究组 & 干预措施
ODSH
Experimental
干预措施: ODSH (Drug)
结局指标
主要结局
Safety by incidence of serious events
时间窗: 12 months
Efficacy by time to platelet recovery
时间窗: 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT02056782Chimerix12
招募中
早期 1 期
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like SyndromeCRS - Cytokine Release SyndromeHLHNCT05306080University of Pennsylvania10
撤回
1 期
A Study to Investigate the Safety and Efficacy of a Novel Furosemide RegimenAcute Decompensated Heart FailureNCT02721511Todd M Koelling, MD
终止
1 期
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaUnresectable Stage III or Stage IV MelanomaNCT02413827Celldex Therapeutics9
已完成
不适用
A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne ScarsAtrophic Acne ScarsNCT02643628Suneva Medical, Inc.45